The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) ...

US-based biopharmaceutical company Trevi Therapeutics has finished enrolling subjects in a Phase IIb trial of investigational Haduvio for treating chronic cough in idiopathic pulmonary fibrosis (IPF) ...

Trevi Therapeutics (TRVI) announced topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC. Haduvio ...

Shares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER study evaluating its investigational therapy Haduvio as a potential ...

The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...

Trevi Therapeutics, Inc.’s TRVI share price has surged by 41.16%, which has investors questioning if this is right time to sell.

Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER ...

Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline Haduvio showed similar efficacy ...

New Haven, Connecticut Tuesday, March 11, 2025, 18:00 Hrs [IST] ...